Announced Mon, 20 Jul · 18:29 IST
Clarification on Q2 FY26 financial results filing format submitted
Compliance View source PDF
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.4%1-day move
₹449.15
prior close
₹449.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.0-1.0-1.0-1.2-2.4-6.1-5.4-5.2——————
Up moveDown movePending
AI summary
Cohance Lifesciences (formerly Suven Pharmaceuticals) told NSE it has resubmitted its Q2 FY26 (quarter ended 30-Sep-2025) financial results in the machine-readable XBRL format on 17 July 2026. Earlier, NSE had asked the company to explain why the results filed on 12-Nov-2025 were submitted in a non-machine readable form. The company had also clarified this in a prior letter dated 2 July 2026 and has now asked the exchange to close the matter.
Likely market impact
Procedural compliance matter closed. No change to reported numbers or business outlook expected.